|
According to the
American Pain Foundation,
each year, more than
25 million people
in the United States experience acute pain as a result
of injury or surgery. Additionally, more than 50
million people in the United States are affected by
ongoing chronic pain!
NPHC
is positioned magnificently to capitalize on this
massive market!
Currently,
NPHC
offers several drug products for sale for the treatment
of pain. The first exciting drug is Cobroxin
which is the
FIRST
over-the-counter (OTC) pain reliever
clinically proven
to treat moderate to severe (Stage 2) chronic pain! Cobroxin
is already available as an oral spray for treating lower
back pain, migraines, neck aches, shoulder pain, cramps
and neuralgia and as a topical gel for treating joint
pain and pain associated with repetitive stress and
arthritis!
This is HUGE!
NPHC is
already generating revenue and they've already
started selling their Cobroxin in
CVS
since this past March! and guess what... the Company
expects to start selling their new drug THIS MONTH in
non other then
Walgreens!
 
The next exciting drug that
NPHC
developed is their Nyloxin
Rx, the
ONLY
non-narcotic and non-addictive treatment for severe
(Stage 3) pain!
NPHC is
anticipating its Nyloxin Rx, a Prescription
Strength STAGE 3 PAIN RELIEF to be
available for distribution throughout the United States
THIS YEAR!
As a prescription-only product,
Nyloxin Rx will only be available through
physicians, hospitals, and pharmacies.
Both Cobroxin and Nyloxin were developed
by Nutra Pharmas wholly-owned drug discovery
subsidiary, ReceptoPharm.
In addition to manufacturing Cobroxin and
Nyloxin, ReceptoPharm is also developing proprietary
therapeutic protein products primarily for the
prevention and treatment of viral and neurological
diseases, including
Multiple Sclerosis
(MS),
Adrenomyeloneuropathy (AMN), and
Human Immunodeficiency
Virus (HIV), and pain in humans. Think
about the revenue potential in each of these markets!!!
Furthermore, just like ARYC our new pick
NPHC
is in the diagnostic industry! The companys
wholly-owned medical devices subsidiary, Designer
Diagnostics, engages in the research and development of
diagnostic test kits designed to be used for the rapid
identification of infectious diseases, such as
Nontuberculous Mycobacteria (NTM)! In fact,
NPHC
owns
11 PATENTS
for the test kit technology! Check them out-
http://www.nutrapharma.com/medical_devices/ip.php
Want more? . . .
NPHC
also operates a
Top- Rated drug
production facility! It just keeps
getting better and better!
NPHC
understands that its investment in manufacturing and its
first-hand knowledge in drug discovery and development
can be very valuable assets to small companies that do
not have these resources or capabilities in-house.
Working with Nutra Pharma/ReceptoPharm, through its ISO
class 5 and GMP
certified facilities, will allow these companies to
avoid considerable clinical development expenses and
allow them to focus on a more important task,
expeditiously getting their products to the next stage!
I highly recommend you listen to
NPHC's
CEO presenting at Nasdaq Marketsite! -
Less than one year ago we saw
NPHC
make a run from as low as $0.02 to as high as $0.99 for
a whopping gain of
4,850%!!
These pharma plays are some of the most profitable
trades on Wall Street!This is why we love small and
micro cap stocks because the potential gains are
unfathomable!
NPHC has now settled back down to
support at the current levels and in our opinion is
setting up for its next big bounce. In our next alert we
will go over why we feel this could become a HUGE short
squeeze play and how our club could potentially profit
BIG from this in the short term!
Start your due diligence and prepare for
next week!
|
